The planning of future clinical trials would likely benefit from the inclusion of both a phospho-specific signal transduction marker (such as pERK) and a proliferation marker (such as Ki67) to allow a true measure of treatment progress at the level of the tumour. The gene discussed is MKI67; the disease is neoplasm.